Executive-Quality Control

Jubilant Pharma Limited is a global integrated pharmaceutical company that offers a diverse range of products and services to customers worldwide. The business is structured into two main segments: Specialty Pharmaceuticals and Generics & APIs. Within Specialty Pharmaceuticals, Jubilant Pharma focuses on Radiopharmaceuticals, Contract Manufacturing of Sterile Injectable, Non-sterile & Allergy Therapy Products. In addition, the company is involved in Generics & APIs, including Solid Dosage Formulations & Active Pharmaceutical Ingredients. Jubilant Generics (JGL), a subsidiary of Jubilant Pharma, operates in India with Research & Development units located in Noida and Mysore. JGL has two manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand, specializing in APIs and Dosage manufacturing. The Mysore manufacturing site, spread over 69 acres, is a USFDA approved facility focusing on APIs production and global sales. The API portfolio emphasizes on Lifestyle driven Therapeutic Areas such as CVS and CNS, targeting complex and newly approved molecules. Jubilant Pharma is a market leader in four APIs and among the top three players in another three APIs, maintaining a high contribution margin. The Roorkee manufacturing facility in Uttarakhand is a state-of-the-art site approved by multiple regulatory bodies including USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA. This facility operates on a B2B model, catering to the EU, Canada, and emerging markets. Both manufacturing units are backed by approximately 500 research and development professionals based in Noida and Mysore. The R&D team is dedicated to developing new products in APIs, Solid Dosage Formulations of Oral Solid, Sterile Injectable, Semi-Solids Ointments, Creams, and Liquids. The company's 80-bed facility conducts all BA/BE studies in-house, holding approvals and certifications from various regulatory authorities globally. JGL's full-fledged Regulatory Affairs & IPR professionals manage a unique portfolio of patents and product filings in regulatory and non-regulatory markets. Jubilant Pharma has shown consistent revenue growth, with revenue reaching INR 53,240 Million during the Financial Year 2018-19, compared to INR 39,950 Million in the Financial Year 2017-18. For more information about the organization, please visit www.jubilantpharma.com.,